612 related articles for article (PubMed ID: 1522359)
1. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M; Berhe D
Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
[TBL] [Abstract][Full Text] [Related]
2. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
3. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological characteristics of leprosy reactions: 15 years experience from north India.
Kumar B; Dogra S; Kaur I
Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):125-33. PubMed ID: 15301592
[TBL] [Abstract][Full Text] [Related]
5. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
[TBL] [Abstract][Full Text] [Related]
6. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
Kar HK; Sharma P
Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for erythema nodosum leprosum.
Manandhar R; LeMaster JW; Roche PW
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
[TBL] [Abstract][Full Text] [Related]
8. Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):436-44. PubMed ID: 1474282
[TBL] [Abstract][Full Text] [Related]
9. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
Feuth M; Brandsma JW; Faber WR; Bhattarai B; Feuth T; Anderson AM
Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
[TBL] [Abstract][Full Text] [Related]
10. Incidence of late lepra reaction among multibacillary leprosy patients after MDT.
Vijayakumaran P; Manimozhi N; Jesudasan K
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714
[TBL] [Abstract][Full Text] [Related]
11. Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum.
Rea TH; Sieling PA
Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):316-27. PubMed ID: 9934358
[TBL] [Abstract][Full Text] [Related]
12. Erythema leprosum--after treatment of Lepromatous Leprosy.
Eickelmann M; Steinhoff M; Metze D; Tomimori-Yamashita J; Sunderkötter C
J Dtsch Dermatol Ges; 2010 Jun; 8(6):450-3. PubMed ID: 19922466
[TBL] [Abstract][Full Text] [Related]
13. Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospective study, comparing the experience of multibacillary patients receiving either 12 or 24 months WHO-MDT.
Balagon M; Saunderson PR; Gelber RH
Lepr Rev; 2011 Sep; 82(3):213-21. PubMed ID: 22125929
[TBL] [Abstract][Full Text] [Related]
14. Occurrence and management of leprosy reaction in China in 2005.
Shen J; Liu M; Zhou M; Wengzhong L
Lepr Rev; 2009 Jun; 80(2):164-9. PubMed ID: 19743620
[TBL] [Abstract][Full Text] [Related]
15. Some unusual type 2 reactions in leprosy.
Ramesh V; Pahwa M
Int J Dermatol; 2010 Feb; 49(2):172-5. PubMed ID: 20465641
[TBL] [Abstract][Full Text] [Related]
16. Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):161-72. PubMed ID: 1522358
[TBL] [Abstract][Full Text] [Related]
17. Unexplained delayed nerve impairment in leprosy after treatment.
Rosenberg NR; Faber WR; Vermeulen M
Lepr Rev; 2003 Dec; 74(4):357-65. PubMed ID: 14750581
[TBL] [Abstract][Full Text] [Related]
18. Reaction cases treated at the Regional Leprosy Training and Research Institute, Aska, Orissa: a retrospective analysis.
Santaram V; Porichha D
Indian J Lepr; 2004; 76(4):310-20. PubMed ID: 16119141
[TBL] [Abstract][Full Text] [Related]
19. [Current guidelines for leprosy treatment].
Flageul B
Bull Soc Pathol Exot; 2003 Jan; 96(5):357-61. PubMed ID: 15015839
[TBL] [Abstract][Full Text] [Related]
20. Epidemiologic characteristics of leprosy reactions.
Scollard DM; Smith T; Bhoopat L; Theetranont C; Rangdaeng S; Morens DM
Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):559-67. PubMed ID: 7868954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
